Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $82.4 million.

  • Sangamo Therapeutics' Total Liabilities rose 1423.98% to $82.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 1423.98%. This contributed to the annual value of $78.9 million for FY2024, which is 432.84% down from last year.
  • As of Q3 2025, Sangamo Therapeutics' Total Liabilities stood at $82.4 million, which was up 1423.98% from $78.0 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Total Liabilities registered a high of $407.7 million during Q1 2021, and its lowest value of $69.3 million during Q2 2024.
  • Over the past 5 years, Sangamo Therapeutics' median Total Liabilities value was $91.4 million (recorded in 2023), while the average stood at $188.4 million.
  • In the last 5 years, Sangamo Therapeutics' Total Liabilities skyrocketed by 11472.45% in 2021 and then plummeted by 7022.92% in 2023.
  • Over the past 5 years, Sangamo Therapeutics' Total Liabilities (Quarter) stood at $346.6 million in 2021, then fell by 22.8% to $267.6 million in 2022, then tumbled by 69.19% to $82.4 million in 2023, then fell by 4.33% to $78.9 million in 2024, then increased by 4.48% to $82.4 million in 2025.
  • Its Total Liabilities was $82.4 million in Q3 2025, compared to $78.0 million in Q2 2025 and $81.3 million in Q1 2025.